Market Research Logo

Fragile X Syndrome - Pipeline Review, H2 2016

Fragile X Syndrome - Pipeline Review, H2 2016

Summary

Global Markets Direct’s, ‘Fragile X Syndrome - Pipeline Review, H2 2016’, provides an overview of the Fragile X Syndrome pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Fragile X Syndrome, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Fragile X Syndrome and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:

  • Certain sections in the report may be removed or altered based on the availability and relevance of data.


  • Scope
    • The report provides a snapshot of the global therapeutic landscape of Fragile X Syndrome
    • The report reviews pipeline therapeutics for Fragile X Syndrome by companies and universities/research institutes based on information derived from company and industry-specific sources
    • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
    • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
    • The report reviews key players involved Fragile X Syndrome therapeutics and enlists all their major and minor projects
    • The report assesses Fragile X Syndrome therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
    • The report summarizes all the dormant and discontinued pipeline projects
    • The report reviews latest news related to pipeline therapeutics for Fragile X Syndrome
    Reasons to buy
    • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
    • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
    • Identify and understand important and diverse types of therapeutics under development for Fragile X Syndrome
    • Identify potential new clients or partners in the target demographic
    • Develop strategic initiatives by understanding the focus areas of leading companies
    • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
    • Devise corrective measures for pipeline projects by understanding Fragile X Syndrome pipeline depth and focus of Indication therapeutics
    • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
    • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


    Introduction
    Global Markets Direct Report Coverage
    Fragile X Syndrome Overview
    Therapeutics Development
    Pipeline Products for Fragile X Syndrome - Overview
    Pipeline Products for Fragile X Syndrome - Comparative Analysis
    Fragile X Syndrome - Therapeutics under Development by Companies
    Fragile X Syndrome - Therapeutics under Investigation by Universities/Institutes
    Fragile X Syndrome - Pipeline Products Glance
    Late Stage Products
    Clinical Stage Products
    Early Stage Products
    Fragile X Syndrome - Products under Development by Companies
    Fragile X Syndrome - Products under Investigation by Universities/Institutes
    Fragile X Syndrome - Companies Involved in Therapeutics Development
    Aelis Farma SAS
    Alcobra Ltd
    AMO Pharma Limited
    Anavex Life Sciences Corp.
    Confluence Pharmaceuticals LLC
    DRI Biosciences Corporation
    Eli Lilly and Company
    GlaxoSmithKline Plc
    GW Pharmaceuticals Plc
    Kareus Therapeutics, SA
    Marinus Pharmaceuticals, Inc.
    Neuren Pharmaceuticals Limited
    Neuron Biopharma SA
    Ovid Therapeutics Inc.
    Sage Therapeutics, Inc.
    Zynerba Pharmaceuticals, Inc.
    Fragile X Syndrome - Therapeutics Assessment
    Assessment by Monotherapy Products
    Assessment by Target
    Assessment by Mechanism of Action
    Assessment by Route of Administration
    Assessment by Molecule Type
    Drug Profiles
    acamprosate calcium - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    ACT-01 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    AMO-01 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    ANAVEX-273 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Bryostatin-1 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    cercosporamide - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Drug to Antagonize mGluR5 for Fragile X Syndrome and 16p11.2 Microdeletion Syndrome - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    flindokalner - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    gaboxadol - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    ganaxolone - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    JRP-655 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    KU-046 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    metadoxine ER - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    NNZ-2591 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    NST-0076 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    SGE-872 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecule for Fragile X-Associated Tremor Ataxia Syndrome - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecule to Activate FMRP for Fragile X Syndrome - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecule to Antagonize CB1R for Fragile X Syndrome and Down Syndrome - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecules to Activate Slack Channels for Fragile X Syndrome - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecules to Agonize Cannabinoid Receptor 2 for Fragile X Syndrome, Pervasive Developmental Disorder and Rett Syndrome - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecules to Block Kv3.1 for Fragile X Syndrome - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecules to Inhibit PI3K for Autism and Fragile X Syndrome - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    SRT-278 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    TC-2153 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    trofinetide - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    ZYN-002 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Fragile X Syndrome - Dormant Projects
    Fragile X Syndrome - Discontinued Products
    Fragile X Syndrome - Product Development Milestones
    Featured News & Press Releases
    Jul 19, 2016: Alcobra Granted European Orphan Drug Designation for Metadoxine in Fragile X Syndrome
    Jun 28, 2016: Results from Phase 2 Exploratory Clinical Study Support Continued Development of Ganaxolone in Fragile X Syndrome
    Jun 27, 2016: Marinus Pharmaceuticals to Host Conference Call on Tuesday, June 28
    Jun 27, 2016: Zynerba Pharmaceuticals Announces Positive Top Line Results from ZYN002 CBD Gel Phase 1 Multiple Rising Dose Trial and Initiation of Phase 2 Study in Adult Epilepsy Patients with Refractory Focal Seizures
    Jun 22, 2016: Neuren receives grant of new Australian patent for trofinetide to treat Autism Spectrum Disorders
    Jun 21, 2016: Bryostatin, a PKC epsilon Activator, Generates New Synapses Through Accumulation of the Synaptic Anchoring Protein PSD-95 at Neuronal Membranes
    Jun 13, 2016: Neurotrope's Chief Scientific Officer Dr. Daniel Alkon Presents at the Gordon Conference: Drugs That Target Common Mechanisms for Synaptic Restoration in Mental Retardation and Alzheimer's Disease
    Jun 07, 2016: AMO Pharma Presents Pre-clinical Data Showing AMO-01 Successfully Inhibits Activated Pathway Associated with Fragile X Syndrome
    Jun 06, 2016: Anavex Announces Positive Preclinical Results with ANAVEX 2-73 in Fragile X - Autism-Related Disorders
    Apr 12, 2016: Cannabis and Cannabinoid Research Publishes Data Demonstrating the Degradation of Cannabidiol to Psychoactive Cannabinoids when Exposed to Simulated Gastric Fluid
    Mar 08, 2016: Neurotrope Announces Publication Demonstrating Synaptic Regeneration with the PKC epsilon Activator Bryostatin, in a Fragile X Disease Late Brain Development Model
    Feb 25, 2016: Zynerba Pharmaceuticals Announces ZYN002 Granted Orphan Drug Designation for Fragile X Syndrome
    Jan 06, 2016: Zynerba Pharmaceuticals Announces Positive Initial Results From ZYN002 CBD Gel Phase 1 Single Rising Dose Trial and Initiation of Phase 1 Multiple Rising Dose Trial
    Dec 07, 2015: Neuren’s trofinetide successful in proof of concept Phase 2 clinical trial in Fragile X syndrome
    Nov 30, 2015: Neuren receives grant of composition patent in Europe for NNZ-2591
    Appendix
    Methodology
    Coverage
    Secondary Research
    Primary Research
    Expert Panel Validation
    Contact Us
    Disclaimer
    List of Tables
    Number of Products under Development for Fragile X Syndrome, H2 2016
    Number of Products under Development for Fragile X Syndrome - Comparative Analysis, H2 2016
    Number of Products under Development by Companies, H2 2016
    Number of Products under Investigation by Universities/Institutes, H2 2016
    Comparative Analysis by Late Stage Development, H2 2016
    Comparative Analysis by Clinical Stage Development, H2 2016
    Comparative Analysis by Early Stage Development, H2 2016
    Products under Development by Companies, H2 2016
    Products under Development by Companies, H2 2016 (Contd..1)
    Products under Investigation by Universities/Institutes, H2 2016
    Fragile X Syndrome - Pipeline by Aelis Farma SAS, H2 2016
    Fragile X Syndrome - Pipeline by Alcobra Ltd, H2 2016
    Fragile X Syndrome - Pipeline by AMO Pharma Limited, H2 2016
    Fragile X Syndrome - Pipeline by Anavex Life Sciences Corp., H2 2016
    Fragile X Syndrome - Pipeline by Confluence Pharmaceuticals LLC, H2 2016
    Fragile X Syndrome - Pipeline by DRI Biosciences Corporation, H2 2016
    Fragile X Syndrome - Pipeline by Eli Lilly and Company, H2 2016
    Fragile X Syndrome - Pipeline by GlaxoSmithKline Plc, H2 2016
    Fragile X Syndrome - Pipeline by GW Pharmaceuticals Plc, H2 2016
    Fragile X Syndrome - Pipeline by Kareus Therapeutics, SA, H2 2016
    Fragile X Syndrome - Pipeline by Marinus Pharmaceuticals, Inc., H2 2016
    Fragile X Syndrome - Pipeline by Neuren Pharmaceuticals Limited, H2 2016
    Fragile X Syndrome - Pipeline by Neuron Biopharma SA, H2 2016
    Fragile X Syndrome - Pipeline by Ovid Therapeutics Inc., H2 2016
    Fragile X Syndrome - Pipeline by Sage Therapeutics, Inc., H2 2016
    Fragile X Syndrome - Pipeline by Zynerba Pharmaceuticals, Inc., H2 2016
    Assessment by Monotherapy Products, H2 2016
    Number of Products by Stage and Target, H2 2016
    Number of Products by Stage and Mechanism of Action, H2 2016
    Number of Products by Stage and Route of Administration, H2 2016
    Number of Products by Stage and Molecule Type, H2 2016
    Fragile X Syndrome - Dormant Projects, H2 2016
    Fragile X Syndrome - Dormant Projects (Contd..1), H2 2016
    Fragile X Syndrome - Discontinued Products, H2 2016
    List of Figures
    Number of Products under Development for Fragile X Syndrome, H2 2016
    Number of Products under Development for Fragile X Syndrome - Comparative Analysis, H2 2016
    Number of Products under Development by Companies, H2 2016
    Number of Products under Investigation by Universities/Institutes, H2 2016
    Comparative Analysis by Clinical Stage Development, H2 2016
    Comparative Analysis by Early Stage Products, H2 2016
    Assessment by Monotherapy Products, H2 2016
    Number of Products by Top 10 Targets, H2 2016
    Number of Products by Stage and Top 10 Targets, H2 2016
    Number of Products by Top 10 Mechanism of Actions, H2 2016
    Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
    Number of Products by Routes of Administration, H2 2016
    Number of Products by Stage and Routes of Administration, H2 2016
    Number of Products by Molecule Types, H2 2016
    Number of Products by Stage and Molecule Types, H2 2016

    Download our eBook: How to Succeed Using Market Research

    Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

    Download eBook

    Share this report